$Ocugen (OCGN.US)$Reuters· 5 mins ago Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Ocu200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
Chew SW
:
Nothing wrong, just many suppressing it as this company pipeline can be life changing , once it pops, the sky is the limit. This counter needs lots of patience to hold
$Ocugen (OCGN.US)$ MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a positive 2-year safety and efficacy update for the Phase 1...
$Ocugen (OCGN.US)$ Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa Monday, 13th January at 6:30 am • 100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years • 100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only p...
$Ocugen (OCGN.US)$ 20 percent not to bad. short been battling... this one looking decent for a squeeze. I figured I'd just look. even though I plan on holding long term..
+1
5
Report
No comment yet
Sign in to post a comment
Trending Stocks
Top Gaining Chinese Stocks Top Gaining Chinese Stocks
Ocugen Stock Forum
Ocugen, Inc. Announces First Patient Dosed in Phase 1 Clinical Trial of Ocu200—a Novel Integrin-Targeting Biologic for Diabetic Macular Edema
MALVERN, Pa., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a positive 2-year safety and efficacy update for the Phase 1...
Ocugen, Inc. Announces Positive 2-Year Data Across Multiple Mutations from Phase 1/2 Clinical Trial of OCU400 —A Novel Modifier Gene Therapy for Retinitis Pigmentosa
Monday, 13th January at 6:30 am
• 100% (9/9) of treated evaluable subjects demonstrated improvement or preservation in visual function compared to untreated eyes at both one and two years
• 100% (9/9) of treated evaluable subjects demonstrated improvement or stabilization in mobility testing, which was only p...
No comment yet